Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CKPTNASDAQ:ENTXNASDAQ:FULCNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.19$4.08$1.75▼$4.50$350.97M1.181.29 million shs3.21 million shsENTXEntera Bio$1.86-4.6%$1.93$1.41▼$2.79$84.54M1.5170,684 shs38,400 shsFULCFulcrum Therapeutics$6.35-1.4%$4.16$2.32▼$10.13$342.77M2.29970,476 shs492,934 shsPRTAProthena$4.58-30.4%$9.38$4.45▼$25.42$246.53M0.11639,124 shs9.65 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics0.00%+0.72%+2.20%+50.72%+127.72%ENTXEntera Bio-4.62%-9.71%-22.50%-9.71%-19.83%FULCFulcrum Therapeutics-1.40%-2.46%+79.89%+91.27%-11.93%PRTAProthena-30.40%-37.17%-52.78%-68.52%-77.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKPTCheckpoint Therapeutics2.1553 of 5 stars1.24.00.04.22.00.80.0ENTXEntera Bio2.0755 of 5 stars3.53.00.00.03.10.80.0FULCFulcrum Therapeutics0.7705 of 5 stars1.22.00.00.03.32.50.0PRTAProthena3.5637 of 5 stars4.23.00.00.03.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKPTCheckpoint Therapeutics 2.33Hold$4.333.42% UpsideENTXEntera Bio 3.00Buy$10.00437.63% UpsideFULCFulcrum Therapeutics 2.43Hold$5.83-8.14% DownsidePRTAProthena 2.44Hold$31.50587.77% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, PRTA, CKPT, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/15/2025FULCFulcrum TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$10.005/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKPTCheckpoint Therapeutics$41K8,560.27N/AN/A($0.47) per share-8.91ENTXEntera Bio$223K379.11N/AN/A$0.36 per share5.17FULCFulcrum Therapeutics$80M4.28N/AN/A$3.80 per share1.67PRTAProthena$137.94M1.79N/AN/A$10.46 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%8/11/2025 (Estimated)ENTXEntera Bio-$8.89M-$0.26N/AN/AN/AN/A-107.24%-92.29%8/8/2025 (Estimated)FULCFulcrum Therapeutics-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/30/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/14/2025 (Estimated)Latest ENTX, PRTA, CKPT, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/A3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/28/2025Q4 2024ENTXEntera Bio-$0.08-$0.06+$0.02-$0.06$0.04 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKPTCheckpoint TherapeuticsN/A0.290.29ENTXEntera BioN/A6.616.61FULCFulcrum TherapeuticsN/A18.4418.44PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKPTCheckpoint Therapeutics22.00%ENTXEntera Bio14.11%FULCFulcrum Therapeutics89.83%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipCKPTCheckpoint Therapeutics2.10%ENTXEntera Bio10.90%FULCFulcrum Therapeutics7.00%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKPTCheckpoint Therapeutics1083.76 million47.81 millionOptionableENTXEntera Bio2045.45 million31.88 millionOptionableFULCFulcrum Therapeutics10053.98 million51.73 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableENTX, PRTA, CKPT, and FULC HeadlinesRecent News About These CompaniesProthena (NASDAQ:PRTA) Downgraded to Neutral Rating by Cantor FitzgeraldMay 28 at 2:28 AM | americanbankingnews.comProthena (NASDAQ:PRTA) Downgraded to Hold Rating by Jefferies Financial GroupMay 28 at 2:28 AM | americanbankingnews.comHC Wainwright Lowers Prothena (NASDAQ:PRTA) Price Target to $14.00May 28 at 1:53 AM | americanbankingnews.comPeninsula biotech Prothena falters — again — and layoffs are on the wayMay 27 at 6:43 PM | bizjournals.comProthena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In PlaceMay 27 at 6:43 PM | seekingalpha.comProthena hits 52-week low amid downgrades after late-stage trial setbackMay 27 at 6:43 PM | msn.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 27 at 1:28 PM | insidermonkey.comProthena's Late-Stage Study for AL Amyloidosis Fails, Stock DownMay 27 at 11:21 AM | zacks.comWhy Is Prothena Stock Trading Lower On Tuesday?May 27 at 7:43 AM | benzinga.comProthena slumps on Phase III birtamimab missMay 26 at 7:10 PM | thepharmaletter.comDeutsche Bank AG Purchases 63,512 Shares of Prothena Co. plc (NASDAQ:PRTA)May 26 at 3:34 AM | marketbeat.comProthena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary EndpointMay 23, 2025 | businesswire.comBNP Paribas Financial Markets Purchases 41,541 Shares of Prothena Co. plc (NASDAQ:PRTA)May 22, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)May 18, 2025 | marketbeat.comCantor Fitzgerald Upgrades Prothena (NASDAQ:PRTA) to "Strong-Buy"May 17, 2025 | marketbeat.comProsight Management LP Sells 65,345 Shares of Prothena Co. plc (NASDAQ:PRTA)May 17, 2025 | marketbeat.comProthena Shareholders Approve Key Amendments at AGMMay 16, 2025 | tipranks.comCantor Fitzgerald Expects Increased Earnings for ProthenaMay 16, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Issues Quarterly Earnings ResultsMay 12, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Receives "Buy" Rating from Chardan CapitalMay 11, 2025 | marketbeat.comProthena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025May 9, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENTX, PRTA, CKPT, and FULC Company DescriptionsCheckpoint Therapeutics NASDAQ:CKPT$4.19 0.00 (0.00%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$4.18 -0.01 (-0.12%) As of 05/27/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Entera Bio NASDAQ:ENTX$1.87 -0.08 (-4.10%) As of 05/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Fulcrum Therapeutics NASDAQ:FULC$6.35 -0.09 (-1.40%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$6.35 0.00 (0.00%) As of 05/27/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Prothena NASDAQ:PRTA$4.58 -2.00 (-30.40%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$4.62 +0.04 (+0.87%) As of 05/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
